Free cash flow has oscillated from -$39.9M in 2024Q2 to +$12.7M in 2025Q2 and back to -$12.2M in 2026Q3, with an OCF-to-net-income ratio of -0.01 in 2025Q3 indicating reported profits were not backed by operating cash, warranting further investigation of timing effects.
Kyntra Bio, Inc. (KYNB) cash flow statement — 14-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | -48.45M | -4.77M | -138M | -315.02M | -145.93M | -82.23M | 81.6M | -78.7M | -76.14M | -66.51M | 7.11M | -18.57M | 22.41M | 25.92M | -5.61M |
| Operating CF Margin % | - | -74.13% | -465.88% | -673.08% | -103.69% | -34.95% | 46.28% | -30.68% | -35.76% | -52.93% | 3.96% | -10.27% | 16.29% | 25.37% | -8.5% |
| Operating CF Growth % | -1265.33% | 96.54% | 56.19% | -115.87% | -77.46% | -200.77% | 203.68% | -3.36% | -14.48% | -1035.75% | - | -182.85% | -13.52% | 562.41% | - |
| Net Income | 34.88M | 183.45M | -47.58M | -284.23M | -293.65M | -290.02M | -189.29M | -76.97M | -86.42M | -120.88M | -58.07M | -85.78M | -59.5M | -14.94M | -32.57M |
| Depreciation & Amortization | 28K | 748K | 2.69M | 9.93M | 10.6M | 14.81M | 22.05M | 21.45M | 6.56M | 6.1M | 6.04M | 5.68M | 4.47M | 5.08M | 5.6M |
| Stock-Based Compensation | 4.34M | 6.58M | 25.21M | 50.77M | 65.6M | 71.16M | 72.72M | 66.27M | 52.14M | 37.54M | 32.13M | 27.68M | 18.7M | 3.44M | 4.56M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -211K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -45.04M | -42.52M | -868K | 28.2M | 1.09M | 61.74M | 1.5M | -3.8M | -30K | 1.71M | 2.69M | 2.89M | 648K | 539K | 542K |
| Working Capital Changes | 9.51M | -153.03M | -117.46M | -119.69M | 70.43M | 60.08M | 174.63M | -85.66M | -48.4M | 9.02M | 24.52M | 30.96M | 58.1M | 31.79M | 16.27M |
| Change in Receivables | -3.73M | -2.54M | -6.74M | 3.43M | 765K | 25.18M | -11.97M | 35.23M | -55.23M | 2M | 4.96M | -1.95M | 4.04M | -8.71M | 14.15M |
| Change in Inventory | 610K | 5.36M | 22.28M | -1.7M | -11M | -14.16M | -9.18M | -6.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -512K | -27.65M | 14.51M | -15.51M | 5.91M | 805K | 17.73M | -3.05M | 3.63M | -714K | -298K | 1.97M | 3.48M | -2.04M | 770K |
| Cash from Investing | -16.72M | 35.42M | 125.99M | 153.66M | 89.12M | -426.97M | 452.49M | 120.02M | -522.12M | 69.87M | 6.62M | -5.87M | -107.29M | 10.78M | 19.15M |
| Capital Expenditures | 0 | -38K | -266K | -2.52M | -3.74M | -5.19M | -3.99M | -5.76M | -8.02M | -8.5M | -1.25M | -1.98M | -8.12M | -6.81M | -744K |
| CapEx % of Revenue | 0% | 0.59% | 0.9% | 5.38% | 2.66% | 2.2% | 2.27% | 2.25% | 3.77% | 6.76% | 0.7% | 1.09% | 5.9% | 6.66% | 1.13% |
| Acquisitions | 3.93M | 0 | 1.05M | 656K | 0 | 0 | -2.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 6.41M | 96.61M | 0 | 0 | -34.99M | -25M | 0 | 7K | 184K | 5K | 0 | 2K | 10K | 2K | 2K |
| Cash from Financing | -42.82M | -86.03M | -255K | 122.75M | 46.78M | -563K | 13.34M | -4.3M | 13.88M | 496.47M | 6.74M | 12.35M | 174.09M | 680K | 6.81M |
| Debt Issued (Net) | -6K | -80.56M | -40K | 73.59M | -538K | -5.89M | -13.02M | -12.33M | -360K | -403K | -403K | -403K | -403K | 421K | -714K |
| Equity Issued (Net) | -20K | -69K | 139K | 48.41M | 4.18M | 12.7M | 37.83M | 20.78M | 29.85M | 506.12M | 9.88M | 1000K | 1000K | 84K | 0 |
| Dividends Paid | 0 | 0 | -2.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -20K | -69K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -42.8M | -5.4M | 1.88M | 748K | 43.13M | -7.37M | -11.46M | -12.75M | -15.61M | -9.24M | -2.74M | -2.24M | 16.86M | 175K | 7.52M |
| Net Change in Cash | -108.07M | -54.31M | -11.51M | -42.01M | -15.52M | -507.17M | 552.13M | 37.01M | -584.4M | 499.88M | 20.46M | -12.13M | 89.12M | 37.46M | 20.29M |
| Free Cash Flow | -48.45M | -4.81M | -138.26M | -317.54M | -184.67M | -112.42M | 77.61M | -84.47M | -84.16M | -75.01M | 5.86M | -20.55M | 14.3M | 19.11M | -6.35M |
| FCF Margin % | -913.65% | -74.72% | -466.78% | -678.46% | -131.22% | -47.77% | 44.02% | -32.92% | -39.52% | -59.69% | 3.26% | -11.36% | 10.39% | 18.71% | -9.63% |
| FCF Growth % | -183.49% | 96.52% | 56.46% | -71.95% | -64.27% | -244.85% | 191.88% | -0.36% | -12.2% | -1380.96% | - | -243.73% | -25.2% | 401.02% | - |
| FCF per Share | -11.96 | -1.19 | -34.55 | -81.59 | -49.33 | -30.43 | 21.59 | -24.37 | -25.03 | -25.69 | 2.33 | -0.34 | 0.25 | 0.40 | -0.48 |
| FCF Conversion (FCF/Net Income) | -1.39x | -0.03x | 2.90x | 1.11x | 0.50x | 0.28x | -0.43x | 1.02x | 0.88x | 0.53x | -0.12x | 0.22x | -0.38x | -1.73x | 0.17x |
| Interest Paid | 0 | 0 | 0 | 54K | 104K | 94K | 135K | 174K | 218K | 255K | 295K | 335K | 377K | -433K | 506K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying KYNB stock.
Kyntra Bio, Inc. (KYNB) generated $-4.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Kyntra Bio, Inc. (KYNB) reported negative free cash flow of $4.8M in 2025, indicating capital requirements exceeded cash from operations.
Kyntra Bio, Inc. (KYNB) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Kyntra Bio, Inc. (KYNB) spent $0.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Net Income Decoupled From Operating Cash
According to the reported cash flow statements, KYNB posted net income of $148.5M in 2025Q3 while operating cash flow was negative $1.8M, an OCF-to-net-income ratio of -0.01 that signals profits were not backed by cash generation.
The gap between reported net income and operating cash flow is the central issue in this dataset, with several quarters showing positive earnings alongside cash outflows. The $148.5M quarterly profit in 2025Q3 appears to be driven by non-cash or non-operating items, since working capital changes of negative $160.3M were the dominant reconciling item rather than underlying operations. Investors should monitor whether these earnings reflect durable economics or accounting-driven swings that do not translate into cash.
Free Cash Flow Oscillates Without Direction
Based on reported figures, KYNB's free cash flow swung from negative $39.9M in 2024Q2 to positive $12.7M in 2025Q2 and back to negative $12.2M in 2026Q3, with FCF margins ranging from negative 172.5% to positive 98.7%.
The FCF series shows no stable trend, and the extreme margin range reflects the company's small and volatile revenue base rather than consistent cash economics. Quarters of positive FCF, such as 2025Q1 and 2025Q2, appear to be exceptions within a longer pattern of cash consumption. The recent 2026Q3 burn of $12.2M suggests the most recent operating trajectory has reverted toward negative cash generation, which warrants further investigation.
Working Capital Swings Dominate Cash Results
As reported in the cash flow statements, working capital changes ranged from negative $160.3M in 2025Q3 to positive $17.8M in 2025Q2, indicating that balance sheet timing has been a larger driver of reported cash flow than core operating activity.
Working capital movements are large relative to operating cash flow in most periods, which makes the reported operating results difficult to interpret on a recurring basis. The 2025Q3 outflow of $160.3M against only $1.8M of operating cash burn implies that other operating assets or liabilities were absorbing substantial cash, though the composition is not disclosed in the supplied data. This pattern may indicate timing effects rather than structural cash generation.
Cumulative Cash Burn Outweighs Reported Profits
Across the ten reported quarters, KYNB's cumulative operating cash flow appears negative, while cumulative net income is distorted by a single large positive quarter, based on the figures supplied.
Summing the quarterly operating cash flows shows net consumption over the window, which contrasts with the $148.5M and $37.9M profit quarters that dominate reported earnings. The divergence suggests that reported profitability is concentrated in a few periods and is not representative of sustained cash generation. Investors should treat the earnings figures with caution until the cash conversion pattern stabilizes.
Positive Quarters May Mask Underlying Burn
The strongest counterpoint is that KYNB's 2025 positive free cash flow quarters may reflect timing rather than durable generation, given the 2026Q3 reversal to negative $12.2M and the absence of any capex or disclosed capital return activity.
Two quarters of positive FCF in 2025 could be read as an emerging inflection, but the subsequent negative quarters and the recent $12.2M burn weaken that interpretation. With capital expenditures near zero and no dividends or buybacks, the cash balance trajectory depends on working capital timing and financing activity not captured in this dataset. The available figures do not establish whether the company has access to external funding, so that factor remains unassessed here.